Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, et al. N Engl J Med 2023 Oct 21. doi: 10.1056/NEJMoa2304753.

Read + Share

Amedeo Smart

Independent Medical Education

Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2023 Oct 21. doi: 10.1056/NEJMoa2304753.
PMID: 37870955